Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 1
1986 1
1990 1
1996 1
1997 1
1999 1
2000 2
2002 2
2003 2
2006 1
2008 8
2009 1
2010 1
2012 3
2013 4
2014 3
2016 1
2017 4
2018 1
2021 1
2022 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
[Clinical manifestations of COVID-19 in children].
Shagieva DR, Rakhmatullin AR, Kutlubaev MA, Tunik VF, Magzhanov RV. Shagieva DR, et al. Among authors: magzhanov rv. Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(8):67-70. doi: 10.17116/jnevro202112108167. Zh Nevrol Psikhiatr Im S S Korsakova. 2021. PMID: 34481438 Review. Russian.
[Anxiety and depressive disorders in Parkinson's disease].
Akhmadeeva GN, Magzhanov RV, Tayupova GN, Bajtimerov AR, Hidijatova IM. Akhmadeeva GN, et al. Among authors: magzhanov rv. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(1. Vyp. 2):54-58. doi: 10.17116/jnevro20171171254-58. Zh Nevrol Psikhiatr Im S S Korsakova. 2017. PMID: 28514334 Review. Russian.
[Thalamic lesion in tick-borne encephalitis].
Ibatullin RA, Magzhanov RV, Usmanov IF. Ibatullin RA, et al. Among authors: magzhanov rv. Zh Nevrol Psikhiatr Im S S Korsakova. 2022;122(8):154-158. doi: 10.17116/jnevro2022122081154. Zh Nevrol Psikhiatr Im S S Korsakova. 2022. PMID: 36036418 Russian.
Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
Freedman MS, Pozzilli C, Havrdova EK, Lemle A, Burcklen M, Larbalestier A, Hennessy B, Sidorenko T, Vaclavkova A, Olsson T; Ponesimod Phase II Study Group. Freedman MS, et al. Neurology. 2022 Aug 23;99(8):e762-e774. doi: 10.1212/WNL.0000000000200606. Epub 2022 Jun 6. Neurology. 2022. PMID: 35667837 Free PMC article. Clinical Trial.
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Cohen JA, et al. Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122652 Clinical Trial.
44 results